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Abstract
Background: In a phase 3 randomized, double-blind, placebo-controlled trial, treatment with idelalisib, a
phosphoinositol-3 kinase δ inhibitor, + bendamustine/rituximab improved progression-free survival (PFS) and overall
survival (OS) in adult patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL). Here we report the
results of health-related quality of life (HRQL) analyses from this study.
Methods: From June 15, 2012 to August 21, 2014, 416 patients with R/R CLL were enrolled; 207 patients were
randomized to the idelalisib arm and 209 to the placebo arm. In the 416 patients randomized to receive
bendamustine/rituximab and either oral idelalisib 150 mg twice-daily or placebo, HRQL was assessed at baseline
and throughout the blinded part of the study using the Functional Assessment of Cancer Therapy–Leukemia (FACT-
Leu) and EuroQoL Five-Dimension (EQ-5D) visual analogue scale (VAS) questionnaires. The assessments were
performed at scheduled patient visits; every 4 weeks for the first 6 months from the initiation of treatment, then
every 8 weeks for the next 6 months, and every 12 weeks thereafter until end of study. Least-squares mean changes
from baseline were estimated using a mixed-effects model by including treatment, time, and treatment-by-time
interaction, and stratification factors as fixed effects. Time to first symptom improvement was assessed by Kaplan-
Meier analysis.
Results: In mixed-effects model analysis, idelalisib + bendamustine/rituximab treatment led to clinically meaningful
improvements from baseline in leukemia-associated symptoms. Moreover, per Kaplan-Meier analysis, the proportion
of patients with symptom improvement was higher and time to improvement was shorter among patients in the
idelalisib-containing arm compared with those who did not receive idelalisib. The physical and social/family FACT-
Leu subscale scores, along with the self-rated health assessed by EQ-VAS, showed improvement with idelalisib over
placebo, but the difference did not reach statistical significance. The functional and emotional FACT-Leu subscale
scores remained similar to placebo.
Conclusions: Addition of idelalisib to bendamustine/rituximab, apart from improving PFS and OS, had a neutral to
beneficial impact on HRQL in patients with R/R CLL, particularly by reducing leukemia-specific disease symptoms.
Trial registration: Clinicaltrials.gov NCT01569295. Registered April 3, 2012.
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Background
In 2018, chronic lymphocytic leukemia (CLL)—the most
common chronic leukemia—represented an estimated
1.2% of all newly diagnosed cancers in the US, with an
estimated 20,940 new CLL cases and 4510 deaths [1].
The age-adjusted rate of CLL incidence is 4.7 per 100,
000 persons per year. Owing to the introduction of new,
improved treatment regimens, the 5-year relative sur-
vival rate increased from 65.5% in 1975 to 84.2% in 2014
[1]. Despite this improvement, CLL remains incurable,
and the majority of patients experience disease relapse
[2]. The risk of relapse is increased in patients with
CLL-associated genomic aberrations [3–6], patients ≥65
years with comorbid conditions [7–10], and refractory
disease [11]. It is not uncommon for these patients to
experience low treatment satisfaction and greatly re-
duced health-related quality of life (HRQL), mostly due
to disease-related symptoms, toxicity of therapies, and
anxiety associated with relapsing disease [12–14]. Des-
pite recommendations to include prospective analyses of
patient-reported outcomes (PROs) as additional end-
points in oncology clinical trials [15–17], PRO-based re-
ports on HRQL in CLL are sparse. Patient-reported
outcomes data can provide important information on
the impact of new treatment regimens, including their
efficacy and toxicity, as seen from the patient’s perspec-
tive [16], and improvement in HRQL often reflects the
efficacy of the new treatment under evaluation [18–21].
Idelalisib, in combination with rituximab, was ap-
proved for the treatment of patients with relapsed CLL
for whom rituximab alone would be considered an
appropriate therapy due to other comorbidities [22]. To
examine the usefulness of idelalisib in additional clinical
scenarios, we conducted a pivotal phase 3, randomized,
multicenter, double-blind, placebo-controlled trial of
idelalisib, a phosphoinositol-3 kinase δ (PI3Kδ) inhibitor,
in combination with bendamustine and rituximab, in
patients with relapsed/refractory CLL (R/R CLL). The ef-
ficacy of the idelalisib/bendamustine/rituximab combin-
ation in this trial was superior to placebo/bendamustine/
rituximab, and substantially improved the primary end-
point of progression-free survival (PFS) as well as the
key secondary endpoint of overall survival (OS) [23].
Prespecified exploratory endpoints in this study in-
cluded assessment of HRQL using the Functional As-
sessment of Cancer Therapy – Leukemia (FACT-Leu)
validated questionnaire [24–28]. The FACT-Leu was
developed as a disease-specific HRQL questionnaire for
patients with leukemia [27, 28], and is composed of sub-
scales scoring the patient’s physical, functional, social/
family, and emotional well-being, as well as leukemia-
specific disease symptoms [27, 28]. Another prespecified
exploratory endpoint was global health status and self-
rated health assessed using the EuroQoL Five-Dimension
(EQ-5D) visual analogue scale (VAS) questionnaires
[29, 30]. We present the results of these prospectively
defined analyses comparing the impact of treatment with
idelalisib combined with bendamustine/rituximab with that
of bendamustine/rituximab/placebo, on patients’ HRQL.
Methods
Study design and participants
This was a phase 3, randomized, multicenter, double-
blind, placebo-controlled study (NCT01569295) in adult
patients who were diagnosed with CLL requiring treat-
ment according to International Workshop on Chronic
Lymphocytic Leukemia criteria [17]. Eligible patients
had measurable lymphadenopathy by computed tomog-
raphy or magnetic resonance imaging, received prior
therapy containing a purine analog or bendamustine and
an anti-CD20 monoclonal antibody, experienced CLL
progression within <36 months since completion of the
last prior therapy, were eligible to receive cytotoxic ther-
apy, and had a Karnofsky Performance Status score of
≥60. Study design and detailed eligibility criteria were
published previously [23].
Ethics, consent, and permissions
The study protocols were approved by the Institutional
Review Boards at each study site. The trial was con-
ducted according to the principles of Good Clinical
Practice and the Declaration of Helsinki. All patients
provided written informed consent.
Treatments and endpoints
Patients received oral idelalisib 150 mg or matching pla-
cebo twice daily. Bendamustine 70 mg/m2 was adminis-
tered intravenously on days 1 and 2 for six 28-day cycles
in both arms. Rituximab was administered intravenously
with each cycle of bendamustine at 375 mg/m2 on day 1
of cycle 1, and 500 mg/m2 on day 1 of cycles 2 to 6. Ide-
lalisib/placebo was given continuously, until disease pro-
gression, death, or intolerable toxicity. Bendamustine
and rituximab were administered for up to a maximum
of 12 and 6 infusions, respectively [23].
The details on primary and secondary endpoints have
been reported [23]. Briefly, the primary endpoint was
PFS; OS, overall response rate, and safety were among
the key secondary endpoints. The prespecified HRQL-
related exploratory endpoints were change from baseline
in HRQL domain and symptom scores based on the
FACT-Leu, and change from baseline in overall health
and single-item dimension scores from the EQ-5D and
EQ-VAS questionnaires. Key time points were the end
of the randomized, double-blind initial period of com-
bination therapy with bendamustine/rituximab at week
24 and the end of the preplanned continuing therapy
period with idelalisib or placebo alone at week 48.
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HRQL assessments
Patient well-being was assessed using the FACT-Leu
questionnaire composed of 44 items measuring physical
well-being (PWB, 7 items), functional well-being (FWB,
7 items), social/family well-being (S/FWB, 7 items),
emotional well-being (EWB, 6 items), and leukemia-
specific concerns (LeuS, 17 items) [28], scored based on
the Functional Assessment of Chronic Illness Therapy-3
scoring guideline and user manual [31]. The subscale
scores represent the sums of each individual item score.
The composite scores include FACT-Leu total score
(range 0–176), which is the sum of all subscales, and the
Trial Outcome Index (TOI, range 0–124), which is the
sum of the PWB, FWB, and LeuS subscales. Higher
scores are associated with better self-reported HRQL.
The EQ-5D questionnaire contains 5 dimensions:
mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression. Each dimension has 3 levels: no
problems, some problems, and extreme problems [32].
The EQ-5D is converted into a single utility index, de-
signed as an international, standardized questionnaire
for evaluation of HRQL [29, 30], by applying the US
preference-weighted index [33]. The EQ-VAS is used to
assess patient’s self-rated health on a 100-mm scale ran-
ging from “Worst imaginable health state” to “Best im-
aginable health state.” The EQ-5D utility and EQ-VAS
scores are considered reliable and valid for assessing
HRQL in cancer patients [34]. Positive changes from
baseline indicate improvement in HRQL.
The surveys were administered every 4 weeks for the
first 6 months from the initiation of treatment, then
every 8 weeks for the next 6 months, and every 12
weeks thereafter until the end of study or until the pa-
tient was no longer receiving blinded study drug for
any reason.
HRQL statistical analyses
The FACT Leu and EQ-5D questionnaire was scored
and processed according to the user manual [32]. The
HRQL questionnaire compliance was defined as a pa-
tient having answered at least 1 question at an assess-
ment time point. The compliance rates for each study
arm and at each time point were calculated as the
number of patients who completed at least 1 question
divided by the total number of patients available at that
assessment time point. The frequency and proportion of
reported problems for each of the five EQ-5D dimen-
sions were summarized at each scheduled assessment.
For the FACT-Leu, EQ-VAS questionnaires, and EQ-5D
utility index, least-squares mean changes from baseline
were estimated using a mixed-effects model, by includ-
ing treatment, time, and treatment-by-time interaction,
and stratification factors as fixed effects. Mixed-effects
model used all available data up to week 84, as < 10% of
placebo patients have data available beyond week 84.
The least-squares means of change from baseline over
time were plotted. The minimally important difference
(MID) ranges were defined for the different subscales
and are summarized in Additional file 1: Table S1. The
lower bound of the MID range was utilized when defin-
ing symptom improvement; an increase of at least 3
points from baseline for PWB, S/FWB, FWB, and EWB,
and 5 points for LeuS (reaching MID). Time to first
symptom improvement was analyzed by the Kaplan-
Meier (KM) method. The hazard ratios with 95%
confidence intervals (CIs) were estimated from a Cox
proportional hazards model without any adjustment and
P-value from log-rank test was reported to examine the
difference between the 2 treatment arms.
The HRQL analyses were based on the intent-to-treat
analysis set, which included all patients randomized
Table 1 Scores for the HRQL questionnaires at baseline
Idelalisib/rituximab/bendamustine, N = 207 n Placebo/rituximab/bendamustine, N = 209 n
FACT-Leu total scorea 125.27 (24.103) 196 123.17 (27.540) 202
Trial outcome index scoreb 86.12 (18.662) 196 84.71 (21.337) 203
Physical well-being 21.77 (5.012) 197 21.39 (5.418) 203
Social/family well-being 21.51 (5.502) 198 21.40 (5.392) 203
Emotional well-being 17.68 (4.215) 198 16.93 (4.902) 204
Functional well-being 17.99 (6.068) 199 17.32 (6.135) 204
Leukemia-specific symptoms 46.31 (10.312) 199 45.95 (12.206) 204
EQ-5D utility index 0.78 (0.217) 197 0.78 (0.228) 195
EQ-VAS 68.8 (17.81) 190 67.4 (19.28) 194
Analyzed in the ITT population. All data presented as mean (SD); n indicates number of patients available for HRQL assessment at baseline
EQ-5D EuroQoL Five-Dimension, FACT-Leu functional assessment of cancer therapy–leukemia, EWB emotional well-being, FWB functional well-being, HRQL health-
related quality of life, ITT intent-to-treat, LeuS leukemia-specific concerns, PWB physical well-being, S/FWB social/family well-being, SD standard deviation, TOI trial
outcome index, VAS visual analog scale
aFACT-Leu Total = LeuS + PWB + S/FWB + EWB + FWB
bTOI = LeuS + PWB + FWB
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e
g
f
Fig. 1 (See legend on next page.)
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in the study regardless of whether study drug was admin-
istered, and with treatment groups designated according
to initial randomization. Nominal P-value threshold of
0.05 was used for significance testing without multiplicity
adjustment. All the analyses were performed using SAS
version 9.2 (Cary, North Carolina).
Results
Key patient characteristics
From June 15, 2012, to August 21, 2014, 416 patients with
R/R CLL were enrolled; 207 patients were randomized to
the idelalisib arm and 209 to the placebo arm. Based on the
results of the formal interim analysis performed in June
2015, the Independent Data Monitoring Committee recom-
mended study unblinding. Although the study is still on-
going, the HRQL data presented herein reflect a data cutoff
date of October 7, 2015, at the time of study unblinding. At
the time of this analysis, 141 (34%) of 416 patients were
continuing in the study; 95 (46%) of 207 in the idelalisib
group and 46 (22%) of 209 in the placebo group.
Patient disposition and demographic and baseline
characteristics were published previously [23]. The pa-
tients received a median (quartile [Q1, Q3]) of 6 (4,
6) cycles of treatment with bendamustine and 6 (5, 6)
with rituximab; the median (Q1, Q3) exposure to
idelalisib and placebo was 14.8 (5.9, 18.9) months and
11.1 (5.8, 15.3) months, respectively. Generally, demo-
graphic and baseline disease characteristics were bal-
anced across the treatment groups [23].
Summary of the efficacy and safety results
The detailed efficacy and safety results were previously
reported at the data cutoff of October 7, 2015 [23], the
same as the present analysis. The addition of idelalisib to
bendamustine/rituximab led to a substantial improve-
ment in the efficacy of the treatment, compared with
bendamustine/rituximab alone [23]. The most common
all-grade adverse events (AEs) were neutropenia and
pyrexia in the idelalisib arm and neutropenia and nausea
in the placebo arm [23].
Patient-reported FACT-Leu and EQ-5D outcomes
Among patients randomized to idelalisib and placebo
arms, similar numbers of patients were available for
HRQL analyses at baseline (Table 1). Mean baseline
scores for the FACT-Leu and EQ-5D questionnaires
were also comparable between the treatment arms
(Table 1).
Assessments of compliance for the FACT-Leu and
EQ-5D questionnaires were conducted over the initial
(See figure on previous page.)
Fig. 1 Mixed-effects model analysis of FACT-Leu. a, FWB; b, EWB; c, PWB; d, S/FWB; e, LeuS; f, TOI score; g, FACT-Leu total score. Curves above the
x-axis indicate positive effects, and curves below the axis show negative effects. Gray area denotes MID range. aP = 0.0525 for treatment
difference. bP = 0.0192 for treatment difference. cP = 0.0343 for treatment difference. CI confidence interval, EWB emotional well-being, FACT-Leu
Functional Assessment of Cancer Therapy–Leukemia, FWB functional well-being, LeuS leukemia-specific symptoms, MID minimally important
difference, PWB physical well-being, S/FWB social/family well-being, TOI trial outcome index
Table 2 Summary of symptom improvement
Idelalisib/bendamustine/rituximab, N = 207 Placebo/bendamustine/rituximab, N = 209
Patients with
MID
improvementa
Time to
symptom
improvementb
Proportion of patients
with any symptom
improvementc
Patients with
MID
improvementa
Time to
symptom
improvementb
Proportion of patients
with any symptom
improvementc
HR
(95% CI)
P-value
PWB 97 (69.3) 12.3 (9.1, 16.1)
N = 140
139 (67.1) 89 (61.8) 20.9 (12.9, 30.1)
N = 144
141 (67.5) 1.28 (0.96, 1.70) 0.1026
S/FWB 82 (59.0) 20.4 (12.1, 39.9)
N = 139
130 (62.8) 79 (52.7) 32.4 (16.3, 72.7)
N = 150
139 (66.5) 1.20 (0.88, 1.63) 0.2663
EWB 99 (62.7) 16.1 (8.9, 23.9)
N = 158
159 (76.8) 103 (61.7) 16.9 (12.4, 24.4)
N = 167
147 (70.3) 1.04 (0.79, 1.37) 0.8357
FWB 102 (60.0) 20.9 (12.1, 39.9)
N = 170
142 (68.6) 100 (55.2) 24.7 (16.1, 44.3)
N = 181
145 (69.4) 1.07 (0.81, 1.42) 0.6321
LeuS 142 (74.7) 8.4 (6.3, 12.7)
N = 190
168 (81.2) 133 (68.6) 12.3 (11, 16.3)
N = 194
168 (80.4) 1.22 (0.96, 1.55) 0.1134
Analyzed in the ITT population. Patients with baseline PWB/S/FWB/FWB > 25, EWB > 21, and LeuS > 63 are not included in the respective analysis of improvement
CI confidence interval, EWB emotional well-being, FWB functional well-being, HRQL health-related quality of life, HR hazard ratio, ITT intent-to-treat, LeuS leukemia-
specific concerns, MID minimally important difference, PWB physical well-being, S/FWB social/family well-being
aData presented as n (%). MID symptom improvement was defined as an increase of ≥3 points from baseline for PWB/S/FWB/FWB/EWB and 5 points for LeuS
bData presented as median (95% CI), weeks. Patients who did not experience a symptom improvement compared to baseline were censored at their last available
HRQL assessment time. Time to symptom improvement (weeks) = (date of first symptom improvement − date of randomization + 1)/7
cData presented as n (%). Patients with any increase from baseline
Montillo et al. Health and Quality of Life Outcomes          (2019) 17:173 Page 5 of 11
144 weeks of study. Compliance rates for both FACT-
Leu and EQ-5D were high and exceeded 80% during
the first 120 weeks of study in both treatment arms
(Additional file 1: Tables S2 and S3).
FACT-Leu
The addition of idelalisib to bendamustine/rituximab
had no significant impact on FWB, EWB, and PWB
compared with placebo/bendamustine/rituximab (Fig. 1a,
b, c). In contrast, idelalisib increased the S/FWB and
LeuS subscale scores, as well as composites TOI and
FACT Leu total score, compared with the placebo arm,
indicating an improvement in HRQL in idelalisib-treated
patients (Fig. 1d, e, f, g). In a mixed-effects model in-
cluding treatment arm (idelalisib vs placebo) and dur-
ation, treatment arm had no significant fixed effect on
any FACT-Leu score. The effect of treatment duration
was significant for FACT-Leu total score (P = 0.0076),
TOI score (P = 0.0103), PWB (P = 0.0017), EWB (P =
0.0142), and LeuS (P = 0.0023); there was no significant
a       b
c       d
e
Fig. 2 Percent of patients with improvements in FACT-Leu subscales (Kaplan-Meier analysis). a, PWB; b, S/FWB; c, LeuS; d, EWB; e, FWB. EWB
emotional well-being, FACT-Leu Functional Assessment of Cancer Therapy–Leukemia, FWB functional well-being, LeuS leukemia-specific symptoms,
PWB physical well-being, S/FWB social/family well-being
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interaction between treatment arm and duration for any
FACT-Leu score. The treatment difference for idelalisib
vs placebo was statistically significant for the LeuS sub-
scale at week 60 (P = 0.0192), and for S/FWB and
FACT-Leu total score at week 4 (P = 0.0525 and P =
0.0343, respectively) (Fig. 1, Additional file 1: Table S4).
The least squares mean changes from baseline in the
LeuS subscale scores were within the MID range of 4 to
7 during the period between week 48 and week 60 in the
idelalisib arm, while the values in the placebo arm did
not reach the MID at any time points (Fig. 1e).
The KM analysis of symptom improvement suggests
that an increased number of patients with the MID im-
provement, as well as shorter time to symptom improve-
ment, were reported for the 5 FACT-Leu subscales in
the idelalisib-containing arm compared with the placebo
arm, but none of the differences reached statistical
significance (Table 2). A higher proportion of patients
treated with idelalisib achieved improvement in PWB, S/
FWB and LeuS subscale scores, but not EWB and FWB
scores, compared with patients treated with placebo
(Fig. 2a–e). Overall, addition of idelalisib to bendamus-
tine/rituximab had a neutral to numerically favorable
effect on change from baseline in FACT-Leu scores of
patients with R/R CLL.
EQ-5D
Proportions of patients reporting level 1 or 2 EQ-5D
health scores at weeks 24 and 48 were generally similar
between the idelalisib and placebo treatment arms.
Slightly fewer idelalisib-treated patients reported ex-
treme problems (level 3) with anxiety/depression and
pain/discomfort at baseline and after 24 and 48 weeks of
treatment compared with patients who received placebo
(Table 3). The EQ-5D utility index and EQ-VAS showed
trends toward improvement with idelalisib relative to
placebo treatment, but these did not reach significance
(Table 4, Fig. 3). In a mixed-effects model including
treatment (idelalisib vs placebo) and treatment duration,
treatment duration had a significant fixed effect for EQ-
5D utility index (P = 0.0169) and EQ-VAS (P = 0.0061);
treatment had no significant fixed effect on either score,
but there was a significant fixed effect of the interaction
between treatment and treatment duration on EQ-5D
utility index (P = 0.0395). Combination therapy with
idelalisib vs placebo did not worsen patient-reported
Table 3 Summary of EQ-5D questionnaire by dimension
Idelalisib/rituximab/bendamustine, N = 207 Placebo/rituximab/bendamustine, N = 209
Dimensions Baseline Week 24 Week 48 Baseline Week 24 Week 48
Anxiety/Depression
Level 1 113 (57.1) 102 (65.8) 85 (66.4) 117 (59.1) 91 (60.3) 70 (66.7)
Level 2 84 (42.4) 50 (32.3) 41 (32.0) 75 (37.9) 55 (36.4) 32 (30.5)
Level 3 1 (0.5) 3 (1.9) 2 (1.6) 6 (3.0) 5 (3.3) 3 (2.9)
Mobility
Level 1 145 (73.6) 119 (76.8) 94 (73.4) 142 (71.4) 112 (74.7) 84 (80.0)
Level 2 52 (26.4) 36 (23.2) 34 (26.6) 55 (27.6) 38 (25.3) 21 (20.0)
Level 3 0 0 0 2 (1.0) 0 0
Pain/Discomfort
Level 1 105 (53.3) 96 (61.9) 77 (60.2) 114 (57.0) 79 (52.3) 63 (60.6)
Level 2 85 (43.1) 54 (34.8) 51 (39.8) 81 (40.5) 69 (45.7) 37 (35.6)
Level 3 7 (3.6) 5 (3.2) 0 5 (2.5) 3 (2.0) 4 (3.8)
Self-Care
Level 1 184 (92.9) 136 (87.7) 115 (89.8) 184 (92.5) 131 (86.8) 92 (87.6)
Level 2 14 (7.1) 19 (12.3) 13 (10.2) 13 (6.5) 20 (13.2) 12 (11.4)
Level 3 0 0 0 2 (1.0) 0 1 (1.0)
Usual Activities
Level 1 126 (63.6) 93 (60.4) 83 (64.8) 122 (61.3) 87 (57.6) 71 (68.3)
Level 2 65 (32.8) 52 (33.8) 45 (35.2) 70 (35.2) 61 (40.4) 31 (29.8)
Level 3 7 (3.5) 9 (5.8) 0 7 (3.5) 3 (2.0) 2 (1.9)
Analyzed in the ITT population. All data represented as n (%)
Level 1: no problems; Level 2: some problems; Level 3: extreme problems
EQ-5D EuroQoL Five-Dimension, ITT intent-to-treat
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health—and resulted in favorable trends in some mea-
sures—in patients with R/R CLL treated with bendamus-
tine/rituximab.
Discussion
In the primary analysis, the addition of idelalisib to
bendamustine/rituximab resulted in superior PFS and
OS compared with bendamustine and rituximab alone,
thus providing a substantial clinical benefit to R/R CLL
patients—a patient population that is difficult to treat
[23]. Apart from treatment goals, a more holistic under-
standing of the impact of treatment including patients’
quality of life is also important, and HRQL data consti-
tutes an important part of treatment evaluation. Because
patients in both the idelalisib and placebo arms received
concurrent chemo-immunotherapy with associated side
effects, idelalisib could not be expected to substantially
improve quality of life (QoL) compared with placebo.
However, there was potential concern that addition of
idelalisib to bendamustine/rituximab would adversely
affect change in QoL relative to treatment with benda-
mustine/rituximab alone.
These prospectively defined HRQL analyses indicate
that idelalisib in combination with bendamustine/rituxi-
mab treatment had a neutral impact on several HRQL
domains in patients with R/R CLL compared with bend-
amustine/rituximab alone. Per mixed-effects model
analyses, the addition of idelalisib to bendamustine/ri-
tuximab did not affect the FWB and EWB subscale
scores, but provided minor improvements in the PWB,
S/FWB, and LeuS subscale scores as well as the FACT-
Leu composite measures TOI and FACT-Leu total score.
Increased LeuS subscale scores in the idelalisib arm were
within the MID range at weeks 48 and 60 and reached
statistical significance at week 60. The KM analysis of the
symptom improvement showed that among idelalisib-
treated patients, time to symptom improvement was
shortened by approximately 4 to 12 weeks for the LeuS,
PWB, and S/FWB subscales, compared with the placebo
arm, and a higher proportion of patients had clinically
meaningful improvements in these HRQL domains.
Idelalisib treatment led to small numerical improve-
ments in HRQL in the global health status, as evidenced
by the EQ-5D results, particularly reduction of the num-
ber of patients who perceived themselves to experience
“extreme problems” within the anxiety/depression and
pain/discomfort dimensions. The mean changes from
baseline in self-rated health, as assessed by EQ-VAS, was
also improved, and reached statistical significance vs pla-
cebo at week 36 when patients had stopped concurrent
chemo-immunotherapy. The rather small differences in
overall quality of life observed between the 2 treatment
arms may be due to side effects from the concurrent
chemo-immunotherapy exerting a dominant effect on
quality of life measurements. However, even the slight
QoL improvement in patients treated with idelalisib vs
placebo in addition to bendamustine/rituximab is valu-
able information considering the AEs recorded in previ-
ous clinical trials of idelalisib [23, 35, 36].
Recently published analyses of PROs assessed in phase
3 randomized trials in patients with relapsed CLL re-
ported that ibrutinib in combination with bendamus-
tine/rituximab vs bendamustine/rituximab alone neither
improved nor adversely impacted HRQL [37], and small
positive improvements were noted with the addition of
ofatumumab to chlorambucil [38] or to fludarabine and
cyclophosphamide [21]. However, apart from the fact
that comparisons of the results across different studies
have several limitations, even indirect comparison of these
findings with the results from our study is difficult because
of different tools used for PRO evaluations (The Functional
Table 4 Mixed-effects model analysis for functional assessment
of cancer therapy using EQ-5D in the ITT population
Treatment differencea LSM (95% CI)
EQ-5D UI EQ-VAS
Week 4 0.03 (−0.01, 0.07) 0.18 (−3.24, 3.61)
P-value 0.1302 0.9167
Week 8 −0.01 (−0.05, 0.04) −1.54 (−5.06, 1.98)
P-value 0.7570 0.3895
Week 12 0.00 (−0.04, 0.05) −1.00 (−4.96, 2.97)
P-value 0.8730 0.6216
Week 16 0.02 (−0.03, 0.07) −0.09 (−3.82, 3.65)
P-value 0.4325 0.9631
Week 20 0.02 (−0.03, 0.06) 0.17 (−3.74, 4.09)
P-value 0.4514 0.9301
Week 24 0.04 (−0.01, 0.08) −0.04 (−3.92, 3.85)
P-value 0.1433 0.9851
Week 30 0.03 (−0.02, 0.08) 0.69 (−3.36, 4.73)
P-value 0.2915 0.7389
Week 36 0.02 (−0.03, 0.07) 1.94 (−2.24, 6.13)
P-value 0.4630 0.3623
Week 42 0.00 (−0.06, 0.06) −1.56 (−5.92, 2.80)
P-value 0.9995 0.4823
Week 48 0.02 (−0.04, 0.07) 1.99 (−2.06, 6.03)
P-value 0.5601 0.3348
Week 60 0.03 (−0.03, 0.09) 1.53 (−3.05, 6.11)
P-value 0.2981 0.5128
Week 72 0.04 (−0.04, 0.11) −0.97 (−6.41, 4.48)
P-value 0.3131 0.7275
Week 84 −0.04 (− 0.11, 0.02) 0.03 (−6.14, 6.20)
P-value 0.2039 0.9921
CI confidence interval, EQ-5D EuroQoL Five-Dimension, UI utility index, ITT
intent-to-treat, LSM least squares means, VAS visual analog scale
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Assessment of Chronic Illness Therapy - Fatigue scale and
European Organisation for Research and Treatment of
Cancer Quality of Life Questionnaire, in the ibrutinib and
ofatumumab studies, and FACT-Leu in this study).
Conclusion
In summary, in patients with incurable diseases such as
CLL, treatment efficacy needs to be balanced with safety
and HRQL. In this study, we found that adding idelalisib
to bendamustine/rituximab—even for those patients
already treated with a prior bendamustine-containing
regimen—improved treatment efficacy with, importantly,
a neutral or beneficial impact on patients’ HRQL. These
HRQL findings provide additional information to bal-
ance the improved efficacy of the combination regimen
with possible safety concerns reported with idelalisib use
[23]. Overall, these results further support the existing
body of evidence indicating that idelalisib treatment ben-
efits patients with R/R CLL.
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